SOLO3 Examines Benefit of Olaparib vs Chemo in PlatinumSensitive Relapsed Ovarian Cancer

SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer

20:00 EDT 4 Jun 2019 | Cancer Networks

This FDA confirmatory phase III study evaluated olaparib vs treatment of physician’s choice in BRCA-mutated, platinum-sensitive relapsed ovarian cancer.

More From BioPortfolio on "SOLO3 Examines Benefit of Olaparib vs Chemo in Platinum-Sensitive Relapsed Ovarian Cancer"